KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...

Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus ...

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at ...

Adjuvant treatment following resection of stage III melanoma is standard practice, based largely on trials that showed it improves recurrence-free survival. However, oncologists have long wondered ...

The rate of appropriate treatment suggestions was 86.6% for Claude3-Opus, 85.7% for GPT4-Turbo, and 75.0% for LLaMa3-70B. Artificial intelligence (AI) can accurately suggest appropriate adjuvant ...

Please provide your email address to receive an email when new articles are posted on . Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated after ...

The randomized, double-blind, placebo-controlled, multicenter study enrolled 992 patients globally. The intent-to-treat ...